文献速递神经肿瘤

术前给予氢化可的松与安慰剂在内镜经蝶窦切除无功能垂体腺瘤患者术中皮质醇水平的比较:双盲随机试验

Comparison of intraoperative cortisol levels after preoperative hydrocortisone administration versus placebo in patients without adrenal insufficiency undergoing endoscopic transsphenoidal removal of nonfunctioning pituitary adenomas: a double-blind randomized trial.
PubMed 文献 · J Neurosurg · 2020-01-24

这项双盲随机试验将40例无肾上腺功能不全的无功能垂体腺瘤患者随机分为术前氢化可的松100 mg组(HC组,n=20)和生理盐水组(C组,n=20),比较术中皮质醇与ACTH水平。HC组术中皮质醇显著高于C组,ACTH显著低于C组。两组均无因肾上腺功能不全导致的术中低血压,术后早期肾上腺功能不全分别见3例和5例,术后3个月垂体功能无差异。

要点

  • 无肾上腺功能不全患者内镜经蝶窦手术前给予氢化可的松100 mg,术中皮质醇显著升高而ACTH显著降低。
  • 两组均无因肾上腺功能不全所致的术中低血压,术后早期肾上腺功能不全HC组3例、C组5例。
  • 术后3个月垂体激素结局(含ACTH缺乏)两组无差异。

核心结论

  • 作者认为,对无肾上腺功能不全、接受内镜经蝶窦手术治疗无功能垂体腺瘤的患者,术前给予类固醇可能是不必要的。
  • 作者指出,仍需大规模研究来确定术前类固醇给药是否对围手术期肾上腺功能不全和术后3个月ACTH缺乏等临床有意义事件有显著影响。

研究设计与样本

  • 双盲随机试验,纳入40例无功能垂体腺瘤患者,随机分为术前氢化可的松100 mg组(HC组,n=20)和生理盐水组(C组,n=20)。
  • 肾上腺功能不全定义为胰岛素耐量试验或快速促肾上腺皮质激素(ACTH)试验峰值皮质醇>18 µg/dl。
  • 排除垂体卒中、近3个月内使用可能影响下丘脑-垂体-肾上腺轴药物、既往脑或肾上腺手术史的患者。

主要发现

  • 麻醉诱导后术中血清皮质醇HC组中位数69.0 µg/dl(IQR 62.2-89.6 µg/dl)vs C组12.7 µg/dl(IQR 8.4-18.2 µg/dl),中位差57.5 µg/dl(95%CI 33.0-172.9 µg/dl)。
  • 硬脑膜切开后皮质醇HC组中位数53.2 µg/dl(IQR 44.9-63.8 µg/dl)vs C组6.4 µg/dl(IQR 4.8-9.2 µg/dl),中位差46.6 µg/dl(95%CI 13.3-89.2 µg/dl)。
  • 肿瘤切除后皮质醇HC组中位数49.5 µg/dl(IQR 43.6-62.4 µg/dl)vs C组9.2 µg/dl(IQR 5.75-16.7 µg/dl),中位差39.4 µg/dl(95%CI 0.3-78.1 µg/dl)。
  • 手术结束时皮质醇HC组中位数46.9 µg/dl(IQR 40.1-63.4 µg/dl)vs C组16.9 µg/dl(IQR 12.1-23.2 µg/dl),中位差32.2 µg/dl(95%CI -42.0至228.1 µg/dl)。
  • 麻醉诱导后血清ACTH HC组中位数3.9 pmol/L(IQR 1.7-5.2 pmol/L)vs C组6.9 pmol/L(IQR 3.9-11.9 pmol/L),p=0.007。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出仍需大规模研究来确定术前类固醇给药是否对围手术期肾上腺功能不全和术后3个月ACTH缺乏等临床有意义事件有显著影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In this double-blind randomized trial, the necessity of preoperative steroid administration in patients without adrenal insufficiency (AI) undergoing endoscopic transsphenoidal surgery (ETSS) for pituitary adenoma was evaluated. METHODS: Forty patients with and without AI, defined as a peak cortisol level > 18 µg/dl on the insulin tolerance test or rapid adrenocorticotropic hormone (ACTH) test, undergoing ETSS for nonfunctioning pituitary adenomas were randomly allocated to treatment with either 100 mg of preoperative hydrocortisone (group HC, n = 20) or normal saline (group C, n = 20). The patients with pituitary apoplexy, the use of a drug within the last 3 months that could affect the hypothalamic-pituitary-adrenal axis, or a previous history of brain or adrenal surgery were excluded. Intraoperative cortisol and ACTH levels were measured after anesthesia induction, dura incision, and tumor removal, and at the end of surgery. Intraoperative hypotension, early postoperative AI, and postoperative 3-month pituitary function were investigated. RESULTS: Intraoperative serum cortisol levels were significantly higher in the HC group than in the C group after anesthesia induction (median 69.0 µg/dl [IQR 62.2-89.6 µg/dl] vs 12.7 µg/dl [IQR 8.4-18.2 µg/dl], median difference 57.5 µg/dl [95% CI 33.0-172.9 µg/dl]), after dura incision (median 53.2 µg/dl [IQR 44.9-63.8 µg/dl] vs 6.4 [IQR 4.8-9.2 µg/dl], median difference 46.6 µg/dl [95% CI 13.3-89.2 µg/dl]), after tumor removal (median 49.5 µg/dl [IQR 43.6-62.4 µg/dl] vs 9.2 µg/dl [IQR 5.75-16.7 µg/dl], median difference 39.4 µg/dl [95% CI 0.3-78.1 µg/dl]), and at the end of surgery (median 46.9 µg/dl [IQR 40.1-63.4 µg/dl] vs 16.9 µg/dl [IQR 12.1-23.2 µg/dl], median difference 32.2 µg/dl [95% CI -42.0 to 228.1 µg/dl]). Serum ACTH levels were significantly lower in group HC than in group C after anesthesia induction (median 3.9 pmol/L [IQR 1.7-5.2 pmol/L] vs 6.9 pmol/L [IQR 3.9-11.9 pmol/L], p = 0.007). No patient showed intraoperative hypotension due to AI. Early postoperative AI was observed in 3 and 5 patients in groups HC and C, respectively. The postoperative 3-month pituitary hormone outcomes including ACTH deficiency were not different between groups. CONCLUSIONS: Preoperative steroid administration may be unnecessary in patients without AI undergoing ETSS for nonfunctioning pituitary adenomas. However, a further large-scale study is needed to determine whether preoperative steroid administration has a significant impact on clinically meaningful events such as perioperative AI and postoperative 3-month ACTH deficiency in these patients.Korean Clinical Trial Registry no.: KCT0002426 (https://cris.nih.go.kr/cris/).

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Lee HC, Yoon HK, Kim JH, et al. Comparison of intraoperative cortisol levels after preoperative hydrocortisone administration versus placebo in patients without adrenal insufficiency undergoing endoscopic transsphenoidal removal of nonfunctioning pituitary adenomas: a double-blind randomized trial. J Neurosurg. 2020. PMID: 31978882. doi:10.3171/2019.11.JNS192381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。